NeoGenomics, Inc. (NEO)
NASDAQ: NEO · Real-Time Price · USD
17.37
+0.58 (3.45%)
At close: Aug 26, 2026, 4:00 PM EDT
17.62
+0.25 (1.44%)
Pre-market: Aug 27, 2026, 7:55 AM EDT

NeoGenomics Revenue

NeoGenomics had revenue of $201.66M in the quarter ending June 30, 2026, with 11.21% growth. This brings the company's revenue in the last twelve months to $766.30M, up 11.19% year-over-year. In the year 2025, NeoGenomics had annual revenue of $727.33M with 10.11% growth.

Revenue (ttm)
$766.30M
Revenue Growth
+11.19%
P/S Ratio
2.91
Revenue / Employee
$306,518
Employees
2,500
Market Cap
2.23B

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 2025727.33M66.77M10.11%
Dec 31, 2024660.57M68.92M11.65%
Dec 31, 2023591.64M81.92M16.07%
Dec 31, 2022509.73M25.40M5.24%
Dec 31, 2021484.33M39.88M8.97%
Dec 31, 2020444.45M35.62M8.71%
Dec 31, 2019408.83M132.09M47.73%
Dec 31, 2018276.74M36.49M15.19%
Dec 31, 2017240.25M8.44M3.64%
Dec 31, 2016231.81M132.01M132.27%
Dec 31, 201599.80M12.73M14.62%
Dec 31, 201487.07M20.60M31.00%
Dec 31, 201366.47M6.60M11.02%
Dec 31, 201259.87M16.38M37.68%
Dec 31, 201143.48M9.11M26.51%
Dec 31, 201034.37M4.90M16.63%
Dec 31, 200929.47M9.45M47.23%
Dec 31, 200820.02M8.51M73.97%
Dec 31, 200711.50M5.03M77.65%
Dec 31, 20066.48M--

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Related Stocks

Company NameRevenue
Sotera Health Company1.22B
OPKO Health587.90M
Veracyte561.90M
CareDx458.09M
GeneDx Holdings454.43M
BillionToOne397.41M
Castle Biosciences357.28M
Adaptive Biotechnologies308.08M
Revenue Rankings